Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Emend Medicare National Coverage Decision Expected By April 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS is accepting public comment on whether aprepitant is a “full replacement” for other anti-emetic treatments in response to an “internally generated” coverage determination request.

You may also be interested in...



Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision

The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.

Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision

The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.

Merck Emend Coverage Decision Will Not Affect Aloxi, MGI Says

The Centers for Medicare & Medicaid Services' initiation of a national coverage determination process for Merck' anti-emetic Emend will have no impact on MGI Pharma's Aloxi, MGI CEO Lonnie Moulder said during a July 14 conference call

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel